Allarity Therapeutics (NASDAQ:ALLR) Releases Earnings Results, Beats Estimates By $0.05 EPS

Allarity Therapeutics (NASDAQ:ALLR) issued its quarterly earnings data on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.05, Zacks reports. The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million.

Allarity Therapeutics Stock Performance

Shares of ALLR stock opened at $1.69 on Wednesday. The firm has a market capitalization of $26.89 million, a price-to-earnings ratio of -2.35 and a beta of 0.52. Allarity Therapeutics has a one year low of $0.77 and a one year high of $2.35. The company has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.19.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Ascendiant Capital Markets boosted their price objective on shares of Allarity Therapeutics from $9.50 to $9.75 and gave the company a “buy” rating in a research report on Friday, April 10th. Wall Street Zen raised shares of Allarity Therapeutics to a “hold” rating in a research note on Saturday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Monday, April 20th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $9.75.

Institutional Trading of Allarity Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Private Advisor Group LLC purchased a new position in shares of Allarity Therapeutics in the 3rd quarter worth about $441,000. Renaissance Technologies LLC grew its holdings in shares of Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after purchasing an additional 181,426 shares during the period. DRW Securities LLC purchased a new stake in shares of Allarity Therapeutics during the 4th quarter worth about $133,000. Citadel Advisors LLC acquired a new stake in Allarity Therapeutics during the 3rd quarter worth approximately $149,000. Finally, XTX Topco Ltd acquired a new stake in Allarity Therapeutics during the 2nd quarter worth approximately $51,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical?stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small?molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid?stage clinical trials.